Press release
Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies
Broad method of use patent protection for COM902, a potential best-in-class reduced Fc, clinical stage, anti-TIGIT antibody, in triple combination with any
About this update from Compugen Ltd.
[{"type":"text","content":"Broad method of use patent protection for COM902, a potential best-in-class reduced Fc, clinical stage, anti-TIGIT antibody, in triple combination with any anti-PD-1 antibody and any anti-PVRIG antibody for the treatment of cancerFurther strengthens Compugen's IP portfolio across DNAM-1 axis checkpoint inhibitorsHOLON, Israel, Nov. 27, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the United States Patent and Trademark Office (USPTO) has granted the Company a new patent covering method of use for COM902, the Company's potential best-in-class reduced Fc, clinical stage antibody targeting TIGIT, and additional TIGIT backup antibodies in triple combination with any anti-PD-1 antibody and any anti-PVRIG antibody for the treatment of cancer.\n\nU.S. Patent No. 12152084 titled \"Triple combination antibody therapies\" augments patents previously issued to Compugen by expanding and protecting the use of COM902 and backup antibodies for treating cancer patients, to include the triplet combination of COM902 with any anti-PD-1 antibody and any anti-PVRIG antibody.\n\"Protecting COM902 in combination with any anti-PVRIG antibody and any anti-PD-1 antibody is an important part of our strategy to bring innovative treatments to patients and value to our shareholders,\" said Anat Cohen-Dayag, Ph.D., President, and Chief Executive Officer of Compugen. \"Recent developments in the TIGIT landscape point to the potential advantage of anti-TIGITs without an active Fc binder such as COM902. Our data also suggest that blocking TIGIT may be insufficient to provide optimal anti-tumor activity in certain tumor types, including those non-responsive to PD-1 inhibition, and blocking PD-1 and PVRIG in parallel may be needed to provide optimal benefit. In our next study we plan to evaluate our potential first-in-class, anti-PVRIG antibody, COM701, in an adaptive platform trial designed to first establish its monotherapy benefit and as a potential backbone for future drug combinations, including with COM902, anti-PD-1 and others.\"\nU.S. Patent No. 12152084 is expected to expire no earlier than August 2037 in the United States.\nAbout Compugen Compugen is a clinical-stage therapeutic discovery and development company utilizing i...